saroglitazar

Modify Date: 2024-01-06 06:29:59

saroglitazar Structure
saroglitazar structure
Common Name saroglitazar
CAS Number 495399-09-2 Molecular Weight 439.56700
Density N/A Boiling Point N/A
Molecular Formula C25H29NO4S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of saroglitazar


Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.

 Names

Name (2S)-2-ethoxy-3-[4-[2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl]ethoxy]phenyl]propanoic acid
Synonym More Synonyms

 saroglitazar Biological Activity

Description Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
Related Catalog
Target

PPARα:0.65 pM (EC50, HepG2 cell)

PPARγ:3 nM (EC50, HepG2 cell)

In Vivo In db/db mice, 12-day treatment with Saroglitazar (0.01-3 mg/kg per day, orally) causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose. A 90-day repeated dose comparative study in Wistar rats and marmosets confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel[1].
Animal Admin Rats: Rats randomize based on body weights and are divided into three equal groups and receives the daily administration of vehicle (50% w/v honey for marmoset and 0.1% carboxymethylcellulose for Wistar rats) or Saroglitazar (1.5 and 15 mg/kg per day) for 90 days by oral gavage[1]. Mice: Male C57BL/6J-db/db mice are bled on day 0 to determine pretreatment serum glucose and TG. During next 12 days, each animal is dosed (by oral gavage) with vehicle (0.5% sodium carboxymethyl cellulose) or Saroglitazar (0.01, 0.03, 0.1, 0.3,1, and 3 mg/kg per day) or pioglitazone (60 mg/kg per day) and on day 12 of the treatment, blood samples are collected (1 h after dosing) from orbital sinus under light ether anesthesia. The serum is isolated and analyzed for glucose, TG, free fatty acid (FFA), and insulin levels[1].
References

[1]. Jain MR, et al. Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015 Jun;3(3):e00136.

 Chemical & Physical Properties

Molecular Formula C25H29NO4S
Molecular Weight 439.56700
Exact Mass 439.18200
PSA 85.99000
LogP 5.29660
Storage condition 2-8℃

 Synonyms

Saroglitazar
UNII-E0YMX3S4JD
Lipaglyn
Top Suppliers:I want be here


Get all suppliers and price by the below link:

saroglitazar suppliers


Price: $383/10mM*1mLinDMSO

Reference only. check more saroglitazar price